[
    [
        {
            "time": "",
            "original_text": "CRO概念持续回暖，机构：新政释放资源，利好行业长期发展",
            "features": {
                "keywords": [
                    "CRO概念",
                    "持续回暖",
                    "新政",
                    "释放资源",
                    "利好",
                    "长期发展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "CRO概念持续回暖，机构：新政释放资源，利好行业长期发展",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本概念股恩捷股份再创新高，泰格医药、广联达、凯莱英、健帆生物跟涨",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "恩捷股份",
                    "新高",
                    "泰格医药",
                    "广联达",
                    "凯莱英",
                    "健帆生物",
                    "跟涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科技",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本概念股恩捷股份再创新高，泰格医药、广联达、凯莱英、健帆生物跟涨",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "公司研究：「凯莱英（002821）」高瓴豪掷10亿CDMO",
            "features": {
                "keywords": [
                    "凯莱英",
                    "高瓴资本",
                    "10亿",
                    "CDMO"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司研究：「凯莱英（002821）」高瓴豪掷10亿CDMO",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]